Where do sulphonylureas fit in the type 2 diabetes guidelines?
Sulphonylureas act by binding to sulphonylurea receptors and stimulating insulin secretion from pancreatic beta cells. This class of oral hypoglycaemic agents is still widely used in the management of type 2 diabetes in patients where lifestyle changes alone are insufficient. Although the older-gene...
Saved in:
| Main Author: | Gail Mkele |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2014-07-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4190 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
What’s the latest on sulphonylureas in the management of type 2 diabetes?
by: Gail Mkele
Published: (2013-12-01) -
Improving the Glimepiride Efficacy in Type 2 Diabetes Treatment: A Review of the Potential Advantages and Disadvantages of Glimepiride as Hypoglycemic Oral Medication.
by: Gehad Abdelazeem Elshamy, et al.
Published: (2025-06-01) -
Modern antihyperglycemic therapy: safety and efficacy of glimepiride
by: Lyudmila Alexandrovna Ruyatkina, et al.
Published: (2012-06-01) -
Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients
by: Ghada S. Rasool, et al.
Published: (2024-01-01) -
Simultaneous HPLC of Metformin, Glipizide and Gliclazide, and Metformin Uptake and Protection of HEI-OC1 from Hyperglycaemia
by: Ahmed Gedawy, et al.
Published: (2024-11-01)